Skip to content
Research/Mitochondrial Health/Cysteamine Pantetheine Disulfide

Cysteamine Pantetheine Disulfide

Cysteamine-pantetheine disulfide is a compound that may play a role in mitochondrial health by influencing coenzyme A metabolism. Its potential impact on energy production and cellular health makes it relevant for longevity and health optimization. However, its clinical applications are still largely unexplored.

Intelligence Profile

Research Papers

Research on Cysteamine Pantetheine Disulfide (TTI-0102) covers various biochemical and therapeutic aspects. Below is a synthesis of key studies and trials:

Biochemical and Mechanistic Studies:

  1. Vanin-1's Role in Oxidative Stress: A study from 2015 in "Current Medicinal Chemistry" explored how Vanin-1 and its catalytic products impact the liver during normal and oxidative stress. The findings suggest that alterations in these biochemical processes may influence cellular responses and disease states (PMID: 26549544).

  2. Metabolism Tracking: A 2013 study in "Analytical Chemistry" used an innovative technique to track the metabolism of related compounds, including cystamine and pantethine. This research provides insight into how these compounds are processed in the body and influences drug development (PMID: 24215585).

  3. Disulfide Modifications in Cell Signaling: The 2005 paper in "Free Radical Research" focused on the significance of disulfide modifications, including S-cysteaminyl, in cellular signaling, indicating potential pathways for therapeutic targeting (PMID: 16036322).

  4. Pantetheinase Inhibition: A 1994 study in the "European Journal of Biochemistry" investigated the inhibition of pantetheinase by disulfides, which may influence therapeutic strategies involving enzyme modulation (PMID: 7957261).

  5. Cysteamine in Lipid Metabolism: The 1987 research in "Atherosclerosis" examined pantethine's effects on lipid metabolism, proposing cysteamine as a mediator in modulating lipids in vitro and in vivo (PMID: 3689482).

  6. Metabolism and Hormone Depletion: The studies from 1985 delved into pantethine's metabolism in cystinosis (PMID: 4056044) and its effects on hormone levels like somatostatin and prolactin in rats, shedding light on its potential systemic impacts (PMID: 2862009).

Clinical Trials:
Cysteamine Pantetheine Disulfide (TTI-0102) has been explored in several clinical trials:

  1. COVID-19 Trial (NCT05212662): This Phase 2 trial was withdrawn and aimed to evaluate TTI-0102 in patients with mild to moderate COVID-19.

  2. Leigh Syndrome Spectrum Study (NCT06990984): Planned as a Phase 2, dose-ranging study in adults and children, this trial is not yet recruiting, aiming to understand TTI-0102's effects on Leigh Syndrome.

  3. MELAS Patients Study (NCT06644534): Completed Phase 2 trial assessed TTI-0102 versus placebo in patients with MELAS, a mitochondrial disorder, providing valuable data on efficacy and safety.

  4. TBI Trial for Veterans (NCT04262895): Also withdrawn, this study was designed to evaluate TTI-0102’s potential benefits for veterans with traumatic brain injury in a combined Phase 1/2 trial.

Disclaimer: This summary is for informational purposes only and not a substitute for professional medical advice.

Free account required

Research papers requires a free AXIFI account to access clinical data, safety profiles, and research papers.